Deals channel feed

Gary Glick (Scorpion Therapeutics)

UP­DAT­ED: Se­r­i­al en­tre­pre­neur Gary Glick sells an­oth­er one of his star­tups for $229M — this time to an un­like­ly buy­er

Gary Glick has proven himself, time and again, a nifty startup artist. After selling Lycera to Celgene, he held a streak for IFM Therapeutics — carving a plate of inflammation programs each time and turning the resulting subsidiary over to Big Pharma, while keeping the core discovery unit — and more recently lined up $270 million for precision oncology work at Scorpion.

His latest deal, though, looks a bit different.

Kerry Blanchard, Everest CEO

Trans-Pa­cif­ic pow­er play­er Ever­est jumps on mR­NA vac­cine deal with Prov­i­dence, pay­ing $100M up­front to tap plat­form play

Everest is jumping aboard the Covid-19 mRNA vaccine train.

While China has used other vaccine technologies to vaccinate its population, companies are starting to explore the use of mRNA vaccines in Asian markets. Everest is now the latest company to focus on the Chinese market in a deal with Canadian biotech Providence Therapeutics.

As part of the deal, Providence will get $100 million upfront in cash, combined with an additional up to $400 million in profit-sharing on the Covid-19 vaccines and milestone payments on collaborative and additional products.

Ken Mills, Regenxbio president and CEO

Ab­b­Vie dives deep­er in­to eye care, pay­ing $370M cash — with a $1.4B sweet­en­er — to part­ner on VEGF gene ther­a­py

AbbVie is expanding the ophthalmology segment of their pipeline today, bagging a gene therapy now in pivotal trials for wet age-related macular degeneration for a whopping $370 million in cash and adding $1.38 billion in milestone cash as a sweetener. And its new partners at Regenxbio also get support for future trial work.

In exchange, AbbVie gets to take the lead on the global commercialization effort — if it works — along with development work, with Regenxbio $RGNX jumping in alongside in the US.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

Emily Leproust, Twist CEO

Boehringer In­gel­heim taps a pop­u­lar an­ti­body dis­cov­ery play­er for ac­cess to drug 'li­brary of li­braries'

Over the past two years, Twist Bioscience — one of the most relied upon companies in biotech and academia for its DNA synthesis services — has been shifting into therapeutics, striking dozens of deals with pharma companies for access to its antibody “library of libraries.”

But none so far can match the deal they’ve just inked with Boehringer Ingelheim.

Boehringer will dole out up to $710 million in milestones to use Twist’s libraries to discover antibodies against a broad range of undisclosed targets, the companies announced on Thursday. The pharma giant will also pay an undisclosed upfront fee for each program that takes off.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

Mike Garrett, Flamingo

Io­n­is col­lab­o­ra­tor Flamin­go is ready to take flight with 3 an­ti­sense drugs in the clin­ic and mys­te­ri­ous RNA in its sights

As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect. But one class of RNA has mostly stumped researchers — until now.

Flamingo Therapeutics officially debuted Thursday with three clinical and one preclinical cancer drugs handed off from antisense guru Ionis, and an intriguing if unproven discovery engine gunning for mysterious long non-coding RNA targets.

Dave Ricks, Eli Lilly

Eli Lil­ly bets on an RNA base edit­ing out­fit lever­ag­ing the body's own en­zymes to re­verse mu­ta­tions

With its controversial Alzheimer’s med donanemab nearly ready for FDA scrutiny, Eli Lilly has grown more emboldened in its efforts to become the top dog in neuroscience. A new partnership with a quiet RNA editing player focused around neuroscience could now add even more bite to Lilly’s bark.

Lilly will pay $50 million in upfront cash and equity and up to $1.25 billion in downstream milestones for access to five RNA editing candidates from Dutch biotech ProQR Therapeutics, which is using edited oligonucleotides to kick off an RNA base editing system initiated by the body’s own enzymes, the partners said Wednesday.

Rahul Singhvi, Resilience CEO

Months af­ter land­ing Cana­di­an site from gov­ern­ment, Re­silience an­nounces a big mR­NA part­ner

Bob Nelsen’s latest project, dreamed up out of anger, has been focused on becoming the Amazon Web Services of drug manufacturing, with the ability to scale in the most efficient way possible. It has now partnered with one of the most influential players in the pandemic response.

Resilience will start making mRNA for Moderna’s Covid-19 vaccine at its new site in Canada, the company announced Wednesday.

Paul Hudson, Sanofi CEO (Raphael Lafargue/Abaca/Sipa USA; Sipa via AP Images)

Sanofi picks up Kad­mon and its trans­plant drug in $1.9B buy­out, giv­ing Sam Wak­sal 2 Big Phar­ma buy­outs un­der his belt

It’s not just hot spaces that Paul Hudson wants Sanofi to lead in.

The CEO’s latest, $1.9 billion M&A gamble points straight to Kadmon $KDMN and its newly approved drug, Rezurock, which is billed as a first-in-class treatment for chronic graft-versus-host disease — and a strong addition to Sanofi’s transplant portfolio.

For Kadmon, the buyout marks a sweet reward at the end of an uphill journey that spanned more than a decade and vindication for a notorious name in biotech, even if the ultimate price is actually lower than its IPO price five years ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,800+ biopharma pros reading Endpoints daily — and it's free.

Dominique Bridon, Diaccurate CEO

Mer­ck KGaA en­trusts se­cre­tive start­up with a mid-stage can­cer drug tar­get­ing mas­ter sig­nal­ing path­way

A secretive French biotech has imported a drug from Germany’s Merck KGaA that will leapfrog the small company right into mid-stage testing against cancer.

Diaccurate has in-licensed Merck KGaA’s M2698 — now dubbed DIACC3010 — a “PAM” inhibitor that is geared up for Phase II studies in both solid tumors and hematological malignancies, the French biotech said early Wednesday morning.

Erik van den Berg, AM-Pharma CEO

Years af­ter Pfiz­er passed on a buy­out op­tion, AM-Phar­ma finds a new part­ner for its kid­ney drug

A couple of years ago, Pfizer passed on an option to buy out AM-Pharma and its recombinant human alkaline phosphatase for kidney failure on the heels of some mixed Phase II data. Now, the program has attracted a new partner — and an approval could mean a big payout for AM-Pharma.

Tokyo-based Kyowa Kirin is putting down $23.6 million upfront for exclusive development and commercialization rights to ilofotase alfa in Japan. There’s another $148 million in biobucks on the line, adding up to a $290 million deal with “tiered double-digit royalties” and a drug supply fee.